Stirling C M, Mathieson P, Boulton-Jones J M, Feehally J, Jayne D, Murray H M, Adu D
Glasgow Royal Infirmary, Glasgow, UK.
QJM. 2005 Jun;98(6):443-9. doi: 10.1093/qjmed/hci072. Epub 2005 May 6.
Focal segmental glomerulosclerosis (FSGS) is the least studied of the causes of idiopathic nephrotic syndrome, and there are few specific guidelines for treatment.
To review data from five UK renal units to investigate whether adult patients with FSGS were treated uniformly, and to examine the effect of treatment on proteinuria and survival.
Retrospective record review.
We examined electronic records of patients with idiopathic FSGS for information on baseline clinical parameters, treatment regimens and outcomes.
Of 136 patients with primary FSGS and nephrotic range proteinuria, 76 (56%) were treated with prednisolone and of this group, 59% were treated with additional immunosuppression. Among the treated patients, the total remission rate (complete and partial) was 67%, and one hospital achieved a remission rate of 80%. Treated patients had a significantly higher remission rate than those who were not treated. Remission was associated with a 5-year survival off dialysis of 94%, compared with 53% if remission was not achieved. Baseline serum creatinine and remission were independently associated with survival off dialysis in a multivariate Cox proportional hazards model.
Patients with primary FSGS and nephrotic range proteinuria, who are treated with corticosteroids, are more likely to enter remission than those who are not treated. Remission rates of up to 80% can be achieved with prolonged treatment, and remission is an independent predictor of survival off dialysis. Patients who do not achieve remission have a poor prognosis. Further clarification of optimal treatment regimens requires additional, prospective studies.
局灶节段性肾小球硬化症(FSGS)是特发性肾病综合征病因中研究最少的,且几乎没有具体的治疗指南。
回顾来自英国五个肾脏单位的数据,以调查FSGS成年患者的治疗是否统一,并研究治疗对蛋白尿和生存率的影响。
回顾性记录审查。
我们检查了特发性FSGS患者的电子记录,以获取基线临床参数、治疗方案和结局的信息。
在136例原发性FSGS且蛋白尿达到肾病范围的患者中,76例(56%)接受了泼尼松龙治疗,其中59%还接受了额外的免疫抑制治疗。在接受治疗的患者中,总缓解率(完全缓解和部分缓解)为67%,有一家医院的缓解率达到了80%。接受治疗的患者缓解率明显高于未接受治疗的患者。缓解与透析脱机后的5年生存率为94%相关,而未实现缓解者为53%。在多变量Cox比例风险模型中,基线血清肌酐和缓解与透析脱机后的生存独立相关。
原发性FSGS且蛋白尿达到肾病范围的患者,接受皮质类固醇治疗比未接受治疗的患者更有可能进入缓解期。延长治疗可实现高达80%的缓解率,且缓解是透析脱机生存的独立预测因素。未实现缓解的患者预后较差。需要更多的前瞻性研究来进一步明确最佳治疗方案。